Friday, 16 January 2026
  
Login

Australia's most trusted
source of pharma news

Friday, 16 January 2026
News

mRNA maker gains momentum

Posted 15 January 2026 PM

Moderna has made significant strides across its infectious diseases portfolio, with its seasonal flu vaccine now filed in four countries, including Australia and a Phase 3 study of its H5 pandemic influenza vaccine candidate set to begin, thanks to US$54.3 million in funding.

At the start of the month, the mRNA developer revealed it has now filed mRNA-1010 for marketing authorisation with the FDA, EMA, Health Canada, and the TGA for adults aged 50 years and older following positive trial results.

To see the whole article, please login

Popular

Skills gap threatening pharma
First Aussie redundancies of 2026
Who earned most from the PBS?
mRNA maker gains momentum
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home